Top-Rated StocksTop-RatedNASDAQ:IOVA Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Free IOVA Stock Alerts $14.82 +0.72 (+5.11%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$14.10▼$15.1850-Day Range$7.59▼$17.4752-Week Range$3.21▼$18.33Volume6.19 million shsAverage Volume8.24 million shsMarket Capitalization$4.14 billionP/E RatioN/ADividend YieldN/APrice Target$24.64 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Iovance Biotherapeutics alerts: Email Address Iovance Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside66.2% Upside$24.64 Price TargetShort InterestBearish21.56% of Float Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.34Based on 11 Articles This WeekInsider TradingAcquiring Shares$2.29 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.40) to ($0.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.76 out of 5 starsMedical Sector59th out of 939 stocksBiological Products, Except Diagnostic Industry9th out of 158 stocks 4.5 Analyst's Opinion Consensus RatingIovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.64, Iovance Biotherapeutics has a forecasted upside of 66.2% from its current price of $14.82.Amount of Analyst CoverageIovance Biotherapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted21.56% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Iovance Biotherapeutics has recently increased by 1.54%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIovance Biotherapeutics has received a 65.12% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Iovance Biotherapeutics is -0.88. Previous Next 2.4 News and Social Media Coverage News SentimentIovance Biotherapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Iovance Biotherapeutics this week, compared to 6 articles on an average week.Search InterestOnly 177 people have searched for IOVA on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows64 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,287,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.40% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.40) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -7.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -7.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 6.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About Iovance Biotherapeutics Stock (NASDAQ:IOVA)Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops products for the treatment of advanced melanoma, non-small cell lung cancer, gynecological cancers, and solid tumor cancers, which include TILVANCE-301, LN-145, IOV-LUN-202, IOV-COM-202, C-145-03, IOV-4001, IOV-3001, IOV-GM1-201, IOV-CLL-01, IOV-2001, and C-145-04. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Read More IOVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IOVA Stock News HeadlinesMarch 26, 2024 | fool.com2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall StreetMarch 26, 2024 | seekingalpha.comIovance Biotherapeutics: Initial Amtagvi Launch In FocusMarch 29, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)March 24, 2024 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 1.7%March 23, 2024 | americanbankingnews.comQ1 2024 Earnings Estimate for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Issued By Zacks ResearchMarch 22, 2024 | globenewswire.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)March 22, 2024 | americanbankingnews.comIovance Biotherapeutics, Inc. Expected to Post FY2026 Earnings of ($1.03) Per Share (NASDAQ:IOVA)March 19, 2024 | finance.yahoo.comIovance Biotherapeutics (NASDAQ:IOVA) shareholders are still up 122% over 1 year despite pulling back 7.1% in the past weekMarch 29, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)March 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Silk Road Medical (SILK), Arcellx Inc (ACLX)March 14, 2024 | markets.businessinsider.comPiper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To KnowMarch 7, 2024 | markets.businessinsider.comTruist Securities Maintains Buy Rating for Iovance Biotherapeutics: Here's What You Need To KnowMarch 7, 2024 | fool.com1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?March 6, 2024 | markets.businessinsider.comPositive Outlook for Iovance Biotherapeutics: Buy Rating Justified by Clinical Advancements and Strong FinancialsMarch 6, 2024 | fool.comIovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street AnalystMarch 4, 2024 | markets.businessinsider.comFDA Lifts Clinical Hold On Iovance Biotherapeutics' IOV-LUN-202 Study In Non-Small Cell Lung CancerMarch 4, 2024 | globenewswire.comIovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung CancerMarch 2, 2024 | fool.comCould Iovance Biotherapeutics Stock Help You Become a Millionaire?March 1, 2024 | globenewswire.comIovance Biotherapeutics to Present at Upcoming ConferencesMarch 1, 2024 | markets.businessinsider.comIovance Biotherapeutics: Strong Buy on Amtagvi Launch and Positive Growth ProspectsMarch 1, 2024 | markets.businessinsider.comIovance Biotherapeutics: Strong Start for Amtagvi and Promising Global Expansion Underpin Buy RatingFebruary 29, 2024 | fool.comWhy Iovance Biotherapeutics Stock Got Trounced on ThursdayFebruary 29, 2024 | uk.finance.yahoo.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finanznachrichten.deIovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesFebruary 29, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Merit Medical Systems (MMSI)February 29, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)See More Headlines Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/29/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IOVA CUSIPN/A CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees557Year Founded2013Price Target and Rating Average Stock Price Target$24.64 High Stock Price Target$34.00 Low Stock Price Target$17.00 Potential Upside/Downside+66.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-444,040,000.00 Net MarginsN/A Pretax Margin-37,638.01% Return on Equity-70.93% Return on Assets-55.25% Debt Debt-to-Equity RatioN/A Current Ratio2.79 Quick Ratio2.70 Sales & Book Value Annual Sales$1.19 million Price / Sales3,478.47 Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book6.50Miscellaneous Outstanding Shares279,310,000Free Float250,259,000Market Cap$4.14 billion OptionableOptionable Beta0.63 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Frederick G. Vogt Esq. (Age 50)J.D., Ph.D., Interim CEO, President, General Counsel & Corporate Secretary Comp: $1.39MMr. Jean-Marc Bellemin M.B.A. (Age 51)CFO, Principal Accounting Officer & Treasurer Comp: $932.2kDr. Igor P. Bilinsky (Age 51)Chief Operating Officer Comp: $932.2kDr. Friedrich Graf Finckenstein M.D. (Age 57)Chief Medical Officer Comp: $1.06MMs. Sara PellegrinoVice President of Investor Relations & Public RelationsMs. Tracy WintonSenior Vice President of Human ResourcesMr. Howard B. Johnson M.B.A. (Age 64)Chief Business Officer Mr. James Ziegler M.B.A.Executive Vice President of CommercialDr. Raj K. Puri M.D.Ph.D., Executive VP of Regulatory Strategy & Translational MedicineMr. Brian Shew M.B.A.Senior VP & Head of Digital and Information TechnologyMore ExecutivesKey CompetitorsApogee TherapeuticsNASDAQ:APGEArcellxNASDAQ:ACLXSpringWorks TherapeuticsNASDAQ:SWTXImmunityBioNASDAQ:IBRXImmunovantNASDAQ:IMVTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 669,350 shares on 3/11/2024Ownership: 8.168%Wellington Management Group LLPBought 53,572 shares on 3/5/2024Ownership: 0.056%Goldman Sachs Group Inc.Sold 82,078 shares on 3/1/2024Ownership: 1.439%Perceptive Advisors LLCBought 16,477 shares on 2/26/2024Ownership: 4.681%Chicago Partners Investment Group LLCBought 2,688 shares on 2/23/2024Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions IOVA Stock Analysis - Frequently Asked Questions Should I buy or sell Iovance Biotherapeutics stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IOVA shares. View IOVA analyst ratings or view top-rated stocks. What is Iovance Biotherapeutics' stock price target for 2024? 10 brokerages have issued twelve-month target prices for Iovance Biotherapeutics' stock. Their IOVA share price targets range from $17.00 to $34.00. On average, they predict the company's share price to reach $24.64 in the next twelve months. This suggests a possible upside of 66.2% from the stock's current price. View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts. How have IOVA shares performed in 2024? Iovance Biotherapeutics' stock was trading at $8.13 at the beginning of the year. Since then, IOVA stock has increased by 82.3% and is now trading at $14.82. View the best growth stocks for 2024 here. When is Iovance Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our IOVA earnings forecast. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) posted its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.01. The biotechnology company had revenue of $0.48 million for the quarter, compared to analysts' expectations of $1.44 million. During the same period in the prior year, the company posted ($0.64) earnings per share. What ETFs hold Iovance Biotherapeutics' stock? ETFs with the largest weight of Iovance Biotherapeutics (NASDAQ:IOVA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).ARK Genomic Revolution ETF (ARKG). What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), Xtrackers California Municipal Bond ETF (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX). Who are Iovance Biotherapeutics' major shareholders? Iovance Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.91%), Vanguard Group Inc. (8.17%), Perceptive Advisors LLC (4.68%), Artisan Partners Limited Partnership (1.89%), Balyasny Asset Management L.P. (1.53%) and Goldman Sachs Group Inc. (1.44%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View institutional ownership trends. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IOVA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss Ratings“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.